Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Cullen

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Clinical Chemistry and Laboratory Medicine|April 14, 2019
Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injuryKarolina Minta, Nicholas C Cullen, Faiez Al Nimer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 21, 2023
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomesAntoine Leuzy, Niklas Mattsson-Carlgren, Nicholas C Cullen, et al.
Journal of Alzheimer'S Disease : JAD|March 17, 2020
Cardiac Surgery is Associated with Biomarker Evidence of Neuronal DamageMarek Alifier, Bob Olsson, Ulf Andreasson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction modelsNicholas C Cullen, Shorena Janelidze, Niklas Mattsson-Carlgren, et al.
Alzheimer'S Research & Therapy|November 23, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217Branislav Kovacech, Nicholas C Cullen, Petr Novak, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 14, 2022
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patientsRuben Smith, Nicholas C Cullen, Alexa Pichet Binette, et al.
Nature Aging|April 28, 2023
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinationsNicholas C Cullen, Antoine Leuzy, Sebastian Palmqvist, et al.
Acta Neuropathologica|December 15, 2018
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's diseaseClaudia Cicognola, Gunnar Brinkmalm, Jessica Wahlgren, et al.
JAMA Neurology|December 20, 2021
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Ruben Smith, Nicholas C Cullen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 17, 2023
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort studyGemma Salvadó, Victoria Larsson, Karly A Cody, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Chemistry and Laboratory Medicine|April 14, 2019
Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injuryKarolina Minta, Nicholas C Cullen, Faiez Al Nimer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 21, 2023
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomesAntoine Leuzy, Niklas Mattsson-Carlgren, Nicholas C Cullen, et al.
Journal of Alzheimer'S Disease : JAD|March 17, 2020
Cardiac Surgery is Associated with Biomarker Evidence of Neuronal DamageMarek Alifier, Bob Olsson, Ulf Andreasson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction modelsNicholas C Cullen, Shorena Janelidze, Niklas Mattsson-Carlgren, et al.
Alzheimer'S Research & Therapy|November 23, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217Branislav Kovacech, Nicholas C Cullen, Petr Novak, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 14, 2022
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patientsRuben Smith, Nicholas C Cullen, Alexa Pichet Binette, et al.
Nature Aging|April 28, 2023
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinationsNicholas C Cullen, Antoine Leuzy, Sebastian Palmqvist, et al.
Acta Neuropathologica|December 15, 2018
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's diseaseClaudia Cicognola, Gunnar Brinkmalm, Jessica Wahlgren, et al.
JAMA Neurology|December 20, 2021
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseAntoine Leuzy, Ruben Smith, Nicholas C Cullen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 17, 2023
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort studyGemma Salvadó, Victoria Larsson, Karly A Cody, et al.
Pageof 3